Publications by authors named "Arian Pano"

Claim this Profile
P
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Allan L Klein, Massimo Imazio, Paul Cremer, Antonio Brucato, Antonio Abbate, Arian Pano

N Engl J Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
Silke van Koningsbruggen-Rietschel, Katja Conrath, Rainald Fischer, Sivagurunathan Sutharsan, Axel Kempa, Arian Pano

J Cyst Fibros· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Ozlem Goker-Alpan, Nicola Longo, Marie McDonald, Suma P Shankar, Raphael Schiffmann, Arian Pano

Drug Des Devel Ther· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment.
Christian J Hendriksz, Joseph Muenzer, Adeline Vanderver, Jonathan M Davis, Barbara K Burton, Arian Pano

Mol Genet Metab Rep· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
Arian Pano, Ann J Barbier, Bonnie Bielefeld, David A H Whiteman, David A Amato

Orphanet J Rare Dis· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy.
Roberto Giugliani, Wuh-Liang Hwu, Anna Tylki-Szymanska, David A H Whiteman, Arian Pano

Genet Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
Frederick L Ruberg, Mathew S Maurer, Daniel P Judge, Steven Zeldenrust, Martha Skinner, Arian Pano

Am Heart J· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis